European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vaccines - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz.the use of shingrix should be in accordance with official recommendations.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - varicella zoster virus glycoprotein e antigen - powder and suspension for suspension for injection - varicella zoster virus glycoprotein e antigen 50 mcg - zoster, purified antigen - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in: • adults 50 years of age or older; • adults 18 years of age or older at increased risk of hz.

Canada - English - Health Canada

glaxosmithkline inc - varicella-zoster virus glycoprotein e antigen - suspension - 50mcg - varicella-zoster virus glycoprotein e antigen 50mcg - vaccines

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - recombinant varicella zoster virus glycoprotein e 50ug - suspension for injection - 50 mcg - active: recombinant varicella zoster virus glycoprotein e 50ug excipient: dibasic potassium phosphate monobasic sodium phosphate as dihydrate polysorbate 80 sucrose cholesterol dibasic sodium phosphate dioleoylphosphatidylcholine monobasic potassium phosphate monophosphoryl lipid a quillaja saponaria sodium chloride water for injection - shingrix is indicated for the prevention of herpes zoster (hz) and post-herpetic neuralgia (phn) in: - adults 50 years of age or older; - adults 18 years of age or older at increased risk of hz.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - recombinant varicella zoster virus glycoprotein e - injection, powder, lyophilized, for liposomal suspension - recombinant varicella zoster virus glycoprotein e 50mcg/0.5ml